121 related articles for article (PubMed ID: 34811896)
81. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
[TBL] [Abstract][Full Text] [Related]
82. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
83. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Kang HJ; Chang HM; Kim TW; Ryu MH; Sohn HJ; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Br J Cancer; 2008 Jan; 98(2):316-22. PubMed ID: 18219288
[TBL] [Abstract][Full Text] [Related]
84. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
85. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
86. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
87. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
[TBL] [Abstract][Full Text] [Related]
88. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
89. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
[TBL] [Abstract][Full Text] [Related]
90. Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial.
Yoshioka T; Takahashi M; Sakamoto Y; Okita A; Fukui T; Murakawa Y; Shindo Y; Imai H; Ohori H; Shirota H; Chiba N; Sasahara YI; Nomura T; Fukushima N; Yamaguchi T; Shimodaira H; Ishioka C
Anticancer Res; 2022 Apr; 42(4):2009-2015. PubMed ID: 35347022
[TBL] [Abstract][Full Text] [Related]
91. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
[TBL] [Abstract][Full Text] [Related]
92. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Morgan MA; Sill MW; Fujiwara K; Greer B; Rubin SC; Degeest K; Yamada SD; Waggoner S; Coleman RL; Walker JL; Mannel RS
Gynecol Oncol; 2011 May; 121(2):264-8. PubMed ID: 21277623
[TBL] [Abstract][Full Text] [Related]
93. Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
Jansen EPM; Boot H; Dubbelman R; Verheij M; Cats A
Ann Oncol; 2010 Mar; 21(3):530-534. PubMed ID: 19690058
[TBL] [Abstract][Full Text] [Related]
94. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Yamada S; Fujii T; Yamamoto T; Takami H; Yoshioka I; Yamaki S; Sonohara F; Shibuya K; Motoi F; Hirano S; Murakami Y; Inoue H; Hayashi M; Murotani K; Kitayama J; Ishikawa H; Kodera Y; Sekimoto M; Satoi S
Br J Surg; 2020 Dec; 107(13):1811-1817. PubMed ID: 32638367
[TBL] [Abstract][Full Text] [Related]
95. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
96. Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity.
Lang N; Diciola A; Labidi-Galy I; Ris F; Di Marco M; Mach N; Petignat P; Toso C; Undurraga M; Hubner M
BMJ Open; 2023 Jan; 13(1):e067691. PubMed ID: 36604127
[TBL] [Abstract][Full Text] [Related]
97. INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
Ramos MFKP; Pereira MA; Charruf AZ; Victor CR; Gregorio JVAM; Alban LBV; Moniz CMV; Zilberstein B; Mello ES; Hoff PMG; Ribeiro Junior U; Dias AR
Arq Bras Cir Dig; 2023; 36():e1744. PubMed ID: 37466566
[TBL] [Abstract][Full Text] [Related]
98. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.
Yuan H; Lu S; Shi M; Yang Z; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
Future Oncol; 2023 Dec; 19(38):2517-2523. PubMed ID: 37212686
[TBL] [Abstract][Full Text] [Related]
99. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Mariani A; Zaanan A; Glehen O; Karoui M
Ann Surg Oncol; 2023 Feb; 30(2):816-817. PubMed ID: 36383333
[No Abstract] [Full Text] [Related]
100. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.
Chia DKA; Sundar R; Kim G; Ang JJ; Shabbir A; So JBY; Yong WP
Ann Surg Oncol; 2023 Mar; 30(3):1889-1890. PubMed ID: 36564654
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
